Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study

Objective To identify patients with hypertension with resistant and controlled blood pressure (BP) using electronic health records (EHRs) in order to elucidate practices in the real-world clinical treatment of hypertension and to enable future genetic studies. Design Using EHRs, we developed and validated algorithms to identify patients with resistant and controlled hypertension. Setting An academic medical centre in Nashville, Tennessee. Population European-American (EA) and African-American (AA) patients with hypertension. Main outcome measures Demographic characteristics: race, age, gender, body mass index, outpatient BPs and the history of diabetes mellitus, chronic kidney disease stage 3, ischaemic heart disease, transient ischaemic attack, atrial fibrillation and sleep apnoea. Medication treatment All antihypertensive medication classes prescribed to a patient at the time of classification and ever prescribed following classification. Results The algorithms had performance metrics exceeding 92%. The prevalence of resistant hypertension in the total hypertensive population was 7.3% in EA and 10.5% in AA. At diagnosis, AA were younger, heavier, more often female and had a higher incidence of type 2 diabetes and higher BPs than EA. AA with resistant hypertension were more likely to be treated with vasodilators, dihydropyridine calcium channel blockers and alpha-2 agonists while EA were more likely to be treated with angiotensin receptor blockers, renin inhibitors and beta blockers. Mineralocorticoid receptor antagonists use was increased in patients treated with more than four antihypertensive medications compared with patients treated with three (12.4% vs 2.6% in EA, p<0.001; 12.3% vs 2.8% in AA, p<0.001). The number of patients treated with a mineralocorticoid receptor antagonist increased to 37.4% in EA and 41.2% in AA over a mean follow-up period of 7.4 and 8.7 years, respectively. Conclusions Clinical treatment of resistant hypertension differs in EA and AA patients. These results demonstrate the feasibility of identifying resistant hypertension using an EHR.

[1]  W. Self,et al.  Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department , 2017, Hypertension.

[2]  J. Reilly,et al.  Resistant hypertension in 2017 , 2017, Current opinion in cardiology.

[3]  A. Cai,et al.  Resistant Hypertension: An Update of Experimental and Clinical Findings. , 2017, Hypertension.

[4]  Melissa A. Basford,et al.  Genome-wide study of resistant hypertension identified from electronic health records , 2017, PloS one.

[5]  Paul A. Harris,et al.  PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability , 2016, J. Am. Medical Informatics Assoc..

[6]  A. de la Sierra,et al.  Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study – a randomized controlled trial , 2016, Journal of hypertension.

[7]  A. Kengne,et al.  Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population , 2016, BMC Research Notes.

[8]  M. Uder,et al.  Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.

[9]  Mary Brophy,et al.  Million Veteran Program: A mega-biobank to study genetic influences on health and disease. , 2016, Journal of clinical epidemiology.

[10]  M. Caulfield,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[11]  S. Frey,et al.  Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. , 2015, American journal of hypertension.

[12]  Nilesh J Samani,et al.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis , 2014, Heart.

[13]  D. Calhoun,et al.  Apparent and true resistant hypertension: definition, prevalence and outcomes , 2014, Journal of Human Hypertension.

[14]  L. Tarnow,et al.  Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial , 2013, Journal of hypertension.

[15]  E. McGlynn,et al.  Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. , 2013, Mayo Clinic proceedings.

[16]  R. Brook,et al.  Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network , 2013, Hypertension.

[17]  A. Hofman,et al.  Thiazide-associated hyponatremia: a population-based study. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  Melissa A. Basford,et al.  Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.

[19]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[20]  Didar Singh Risk of thiazide-induced hyponatremia in patients with hypertension. , 2012, The American journal of medicine.

[21]  W. Elliott,et al.  What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.

[22]  Daniel J Buysse,et al.  Resistant hypertension and obstructive sleep apnea in the setting of kidney disease , 2012, Journal of hypertension.

[23]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[24]  Marylyn D. Ritchie,et al.  The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients , 2012, Pharmacogenetics and genomics.

[25]  Tom R. Gaunt,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[26]  B. Egan,et al.  Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2011, Circulation.

[27]  H. Black,et al.  Comparative Efficacy and Safety of Combination Aliskiren/Amlodipine and Amlodipine Monotherapy in African Americans With Stage 2 Hypertension , 2011, Journal of clinical hypertension.

[28]  Hua Xu,et al.  Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin , 2011, J. Am. Medical Informatics Assoc..

[29]  Tien Yin Wong,et al.  Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians , 2011, Nature Genetics.

[30]  Stephen D. Persell Prevalence of Resistant Hypertension in the United States, 2003–2008 , 2011, Hypertension.

[31]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[32]  P. Doris The genetics of blood pressure and hypertension: the role of rare variation. , 2011, Cardiovascular therapeutics.

[33]  Wendy A. Wolf,et al.  The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies , 2011, BMC Medical Genomics.

[34]  P. Zamboli,et al.  Burden of Resistant Hypertension in Hypertensive Patients with Non-Dialysis Chronic Kidney Disease , 2011, Kidney and Blood Pressure Research.

[35]  Joshua C Denny,et al.  Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records , 2010, Genetics in Medicine.

[36]  Son Doan,et al.  An Automated Approach to Calculating the Daily Dose of Tacrolimus in Electronic Health Records , 2010, Summit on translational bioinformatics.

[37]  A. Avogaro,et al.  Use of Electronic Support for Implementing Global Cardiovascular Risk Management , 2010 .

[38]  C. Ferrario Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. , 2010, Life sciences.

[39]  P. O’Reilly,et al.  Faculty Opinions recommendation of Genome-wide association study identifies eight loci associated with blood pressure. , 2009 .

[40]  Charles Rotimi,et al.  A Genome-Wide Association Study of Hypertension and Blood Pressure in African Americans , 2009, PLoS genetics.

[41]  Andrew D. Johnson,et al.  Genome-wide association study of blood pressure and hypertension , 2009, Nature Genetics.

[42]  C. McAdam-Marx,et al.  Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. , 2009, Clinical therapeutics.

[43]  J. Mindell,et al.  Continued Improvement in Hypertension Management in England: Results From the Health Survey for England 2006 , 2009, Hypertension.

[44]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[45]  G. Bakris,et al.  Resistant hypertension: an overview of evaluation and treatment. , 2008, Journal of the American College of Cardiology.

[46]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[47]  Hongyu Zhao,et al.  Rare independent mutations in renal salt handling genes contribute to blood pressure variation , 2008, Nature Genetics.

[48]  F. Fuchs,et al.  Obstructive sleep apnea and resistant hypertension: a case-control study. , 2007, Chest.

[49]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[50]  Keith C. Norris,et al.  Unraveling the racial disparities associated with kidney disease. , 2005, Kidney international.

[51]  Barry R Davis,et al.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. , 2005, JAMA.

[52]  H. Black,et al.  Resistant hypertension revisited: a comparison of two university-based cohorts. , 2005, American journal of hypertension.

[53]  B. Freedman,et al.  Genetic factors in end-stage renal disease. , 2005, Kidney international. Supplement.

[54]  E. Boerwinkle,et al.  Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. , 2005, American journal of human genetics.

[55]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[56]  T. Shafi,et al.  Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients: The Quinapril Titration Interval Management Evaluation Trial , 2004, Hypertension.

[57]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[58]  T. Wong,et al.  Risk factors for thiazide-induced hyponatraemia. , 2003, QJM : monthly journal of the Association of Physicians.

[59]  F. Luft Mendelian forms of human hypertension and mechanisms of disease. , 2003, Clinical medicine & research.

[60]  S. Textor,et al.  Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care , 2002, Hypertension.

[61]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[62]  T. Douglas Bradley,et al.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension , 2001, Journal of hypertension.

[63]  Ali G. Gharavi,et al.  Molecular Mechanisms of Human Hypertension , 2001, Cell.

[64]  M. Burnier,et al.  Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions , 2001, Journal of hypertension.

[65]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[66]  L. Schild,et al.  Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome , 1995, Nature Genetics.

[67]  Morris Schambelan,et al.  Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel , 1994, Cell.

[68]  B. Massie,et al.  A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks , 1990 .

[69]  J. Graves,et al.  Plasma volume in resistant hypertension: guide to pathophysiology and therapy. , 1989, The American journal of the medical sciences.

[70]  N. Franceschini,et al.  Genetics of hypertension: discoveries from the bench to human populations. , 2014, American journal of physiology. Renal physiology.

[71]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[72]  A. Schutte,et al.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. , 2014, Journal of hypertension.

[73]  D. Calhoun,et al.  Resistant hypertension: incidence, prevalence, and prognosis. , 2012, Circulation.

[74]  Yang Qiu,et al.  'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  W. Elliott Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008 , 2012 .

[76]  Kirsten L. Johansen,et al.  US Renal Data System 2011 Annual Data Report , 2012 .

[77]  M. Castanheira,et al.  Prevalence and Antimicrobial Susceptibility Profile of ESBL- and KPC-producing Enterobacteriaceae in the United States (2003 − 2008) , 2010 .

[78]  Kevin B. Johnson,et al.  Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..

[79]  W. Elliott Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2009 .

[80]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[81]  M. Martínez-García,et al.  [Sleep-disordered breathing in patients with difficult-to-control hypertension]. , 2006, Archivos de bronconeumologia.

[82]  J. J. Soler-Cataluña,et al.  Trastornos respiratorios durante el sueño en pacientes con hipertensión arterial de difícil control , 2006 .

[83]  S. Textor,et al.  Comparing Hemodynamic Management to Specialist Care , 2002 .

[84]  The Council for High Blood Pressure Research is pleased to present: The Novartis Award for Hypertension Research. , 2000, Hypertension.

[85]  J. Nedelman,et al.  Race, socioeconomic status, and the development of end-stage renal disease. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  R. Shimkets,et al.  Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. , 1994, Cell.

[87]  W. Leonard,et al.  Blood pressure in blacks and whites and its relationship to dietary sodium and potassium intake. , 1984, Journal of chronic diseases.

[88]  L. Kuller,et al.  Arterial blood pressure and urinary electrolytes. , 1984, Journal of chronic diseases.

[89]  Xiaofeng Zhu,et al.  Genetic Structure, Self-identified Race/ethnicity, and Confounding in Case-control Association Studies , 2022 .